This is a temporary backup site for TRENDS MENA while our primary website is being restored following a regional disruption affecting Amazon Web Services cloud infrastructure in the GCC.

Search Site

Alujain widens 2025 loss

The increase in loss is due to impairment charges, weaker prices.

Masar 2025 net profit $262m

Higher land plot sales boost revenue and operating income.

Tasnee’s 2025 losses deepen

The petrochemicals' company's revenue also fell 17.7 percent.

DP World 2025 revenue $24.4bn

The profit for the year up 32.2% to reach $1.96bn.

BYD 2025 revenue surges

The EV manufacturer reported net profit of $.3.3bn for 9M 2025.

AstraZeneca to move to Dubai Science Park with new sustainable offices ahead of COP28

  • Set to open in Q3 2023, the move is part of the biopharmaceutical giant’s global green agenda
  • The company recently held its first multilateral engagement on health and climate at COP27

Dubai, UAE – In line with this year’s focus on sustainability in the UAE, AstraZeneca has announced plans to construct sustainable offices at Dubai Science Park, a member of TECOM Group.

Set to open in Q3 2023, the move is part of the biopharmaceutical giant’s global green agenda and in-line with “We the UAE 2031” vision and the Year of Sustainability.

The new office design, construction, and materials will meet platinum standards in Leadership in Energy and Environmental Design (LEED) set out by the U.S. Green Building Council (USGBC). The Green Building Classification System is one of the most widely used worldwide and a marker of healthy, efficient, and carbon-saving buildings.

AstraZeneca is a champion of the Sustainable Markets Initiative (SMI) Health Systems Task Force – a public-private partnership committed to accelerating the delivery of net zero healthcare systems. The company recently held its first multilateral engagement on health and climate at COP27, bringing together members of the SMI, the World Health Organisation (WHO) and the Commonwealth Secretariat to announce new joint action to accelerate net zero healthcare in three areas: supply chains, patient care pathways, and clinical trials.